4375-s Kurtoxin

Code:
4375-s
Name:
Kurtoxin
Lys-Ile-Asp-Gly-Tyr-Pro-Val-Asp-Tyr-Trp-Asn-Cys-Lys-Arg-Ile-Cys-Trp-Tyr-Asn-Asn-Lys-Tyr-Cys-Asn-Asp-Leu-Cys-Lys-Gly-Leu-Lys-Ala-Asp-Ser-Gly-Tyr-Cys-Trp-Gly-Trp-Thr-Leu-Ser-Cys-Tyr-Cys-Gln-Gly-Leu-Pro-Asp-Asn-Ala-Arg-Ile-Lys-Arg-Ser-Gly-Arg-Cys-Arg-Ala (Disulfide bonds between Cys12-Cys61, Cys16-Cys37, Cys23-Cys44, and Cys27-Cys46)
(M.W. 7386.4) C324H478N94O90S8
T-type Ca2+ Channel Blocker
Package Price(Yen)
Vial 0.1 mg 30,000

main

Purity:
≧98.0% (HPLC)
Storage:
-20 ℃
Source:
Scorpion, Parabuthus transvaalicus
Production:
Synthetic Product

Solubility: H2O (50 μM)

more information

Category:
Biologically Active Peptides

reference

  1. R.S-I. Chuang, H. Jaffe, L. Cribbs, E. Perez-Reyes, and K.J. Swartz, Nat. Neurosci., 1, 668 (1998). (Original)
  2. S.S. Sidach and I.M. Mintz, J. Neurosci., 22, 2023 (2002). (Pharmacol; Specificity for Ca2+-Channel Blocking Activity)
  3. T. Olamendi-Portugal, B.I. García, I. López-González, J. Van DerWalt, K. Dyason, C. Ulens, J. Tytgat, R. Felix, A. Darszon, and L.D. Possani, Biochem. Biophys. Res. Commun., 299, 562 (2002). (Pharmacol.)
  4. I. López-González, T. Olamendi-Portugal, J.L. De La Vega-Beltrán, J. Van derWalt, K. Dyason, L.D. Possani, R. Felix, and A. Darszon, Biochem. Biophys. Res. Commun., 300, 408 (2003). (Pharmacol.)
  5. H. Nishio, Y. Nishiuchi,M. Is himaru, and T. Kimura, Lett. Pept. Sci., 10, 589 (2003). (Chem. Synthesis & S-S Bond)